Lisa Coco
Nurse Practitioner · Philadelphia, PANPI 1841203726
Payments from drug & device makers
Across 695 payments — averaging $330.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$165K
- Xeris Pharmaceuticals, Inc.$33K
- AstraZeneca$17K
- Sanofi-aventis U.S. LLC$9K
- GSK$3K
- Amgen$880
- plus $3K from 28 others
What the payments were for
- Consulting fees$24,04610%
- Speaking & faculty fees$161,62470%
- Travel & lodging$28,46512%
- Food & beverage$15,3047%
- Education$620%
- Other$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 379 | $164,641 |
| Xeris Pharmaceuticals, Inc. | 80 | $32,518 |
| AstraZeneca(2 entities) | 42 | $17,136 |
| Sanofi-aventis U.S. LLC | 35 | $8,990 |
| GSK | 7 | $2,561 |
| Amgen | 36 | $880 |
| Abbott | 24 | $655 |
| Lilly USA, LLC | 20 | $327 |
| Bayer | 4 | $325 |
| Amarin Pharma, Inc. | 19 | $268 |
| Corcept Therapeutics | 6 | $201 |
| Medtronic | 2 | $139 |
| Ascendis Pharma Endocrinology Inc | 2 | $139 |
| Amphastar Pharmaceuticals, Inc. | 7 | $125 |
| Mannkind Corporation | 4 | $74 |
| Pfizer | 3 | $63 |
| Radius Health, Inc. | 3 | $57 |
| Amryt Pharma Holdings Ltd | 2 | $46 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Neurocrine Biosciences, Inc. | 1 | $34 |
| GRT US Holding, Inc. | 2 | $33 |
| Recordati_rare_diseases_inc. | 2 | $32 |
| Cequr Corporation | 1 | $31 |
| Tolmar, Inc. | 2 | $30 |
| Lifescan, Inc. | 1 | $30 |
| Dexcom, Inc. | 1 | $29 |
| Ascensia Diabetes Care US Inc. | 1 | $26 |
| Averitas Pharma Inc. | 1 | $25 |
| Novartis | 1 | $24 |
| Tandem Diabetes Care, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$80,944
- Ozempic$64,033
- GVOKE HYPOPEN$20,664
- FARXIGA$16,674
- GVOKE PFS$10,259
- SOLIQUA 100/33$4,071
- TOUJEO$3,464
- AREXVY$2,475
- Kerendia$223
- FREESTYLE LIBRE 3$154
- TZIELD$143
- EVENITY$141
- Yorvipath$120
- MINIMED 780G$119
- TEPEZZA$105
- Korlym$102
How this compares
$229,561 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 355 | $493,788 |
| FarxigaDapagliflozin Propanediol | 183 | $181,396 |
| JardianceEmpagliflozin | 106 | $113,238 |
| Tresiba Flextouch U-200Insulin Degludec | 103 | $110,409 |
| MounjaroTirzepatide | 68 | $87,928 |
| TrulicityDulaglutide | 53 | $76,709 |
| Tresiba Flextouch U-100Insulin Degludec | 93 | $59,180 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $51,461 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 83 | $49,110 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 224 | $34,759 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $33,203 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 32 | $32,854 |
| Novolog FlexpenInsulin Aspart | 128 | $31,007 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $25,506 |
| Victoza 3-PakLiraglutide | 12 | $19,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $164,641 | $504,425367 claims |
| AstraZenecaFarxiga | $17,136 | $181,396183 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev | $327 | $179,551133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Philadelphia
- Patricia ManganPhiladelphia$360K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Carolyn GrandePhiladelphia$71K
- Faith MutalePhiladelphia$62K
- Frances RogersPhiladelphia$46K
- Meghan GarabedianPhiladelphia$30K
- Victoria SherryPhiladelphia$10K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.